FSS | PUBLICATIONS
PUBLICATIONS
Explore articles based on work undertaken by Frontier Science Scotland
The ALTTO Trial: Updated Results from the international phase III ALTTO trial (BIG2-06/Alliance N063D)
Presentation of the pre-specified analyses of >5-years follow-up of the Phase III ALTTO trial as shown at the 2017 annual meeting of the American Society of Clinical Oncology and published in the European Journal of Cancer in 2021.
The APHINITY Trial: Results of the Interim Overall Survival Analysis at 6 years’ follow-up
The JCO confirms the invasive disease-free survival benefit from adding pertuzumab to standard adjuvant therapy for patients with node-positive HER2-positive early breast cancer.
A pooled analysis of the Cardiac Events in three adjuvant trials: HERA, NSBAP B-31, and NCCTG 9831 (Alliance Trials)
Breast Cancer Research and Treatment published that Adjuvant trastuzumab should be considered a safe treatment from a cardiac standpoint for most patients. Further research is needed to individualize prevention and management of trastuzumab-associated cardiotoxicity.
The APHINITY Trial: Results of the Primary Analysis
An article published in the New England Journal of Medicine (NEJM) reports that pertuzumab, when added to chemotherapy and trastuzumab, significantly improved the rates of invasive-disease–free survival among patients with HER2-positive early breast cancer.
The HERA Trial: Final Analysis Results
An article published in The Lancet shares the results from the final analysis of the HERceptin Adjuvant (HERA) trial.
The NordICC Study: Population-based colonoscopy screening for colorectal cancer: a randomized clinical trial.
JAMA Internal Medicine reports on the investigation into participation rates, adenoma yield, performance, and adverse events of population-based colonoscopy screening in several European countries.
The ALTTO Trial: Results of the Primary Analysis
An article in the JCO reports that adjuvant treatment that includes lapatinib did not significantly improve Disease-Free Survival compared with trastuzmab alone and added toxicity. One year of adjuvant trastuzumab remains standard of care.
The Neo-ALTTO Trial: Pathological complete response after neoadjuvant anti-HER2 therapy
Findings from this study confirm that patients who achieve pathological complete response after neoadjuvant anti-HER2 therapy have longer event-free and overall survival than do patients without pathological complete response.
The HERA Trial: Cardiac Events at 8 years median follow-up
The JCO confirms the low incidence of cardiac events for trastuzumab given sequentially after chemotherapy and radiotherapy.